Diagnosis and management of hyperprolactinemia

CMAJ. Canadian Medical Association Journal

Volumn 169, Issue 6, 2003, Pages 575-581

  Serri, Omar ^a   Chik, Constance L ^b   Ur, Ehud ^c   Ezzat, Shereen ^d,e  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c DALHOUSIE UNIVERSITY   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; HYPOTHALAMUS HORMONE; PERGOLIDE; PROLACTIN; QUINAGOLIDE;

AGE; CANCER SURGERY; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG COST; EVALUATION; GASTROINTESTINAL SYMPTOM; HORMONAL REGULATION; HORMONE DETERMINATION; HUMAN; HYPERPROLACTINEMIA; HYPOPHYSIS TUMOR; HYPOTHYROIDISM; NUCLEAR MAGNETIC RESONANCE IMAGING; PREGNANCY; PREMENOPAUSE; PREVALENCE; PROLACTIN BLOOD LEVEL; PROLACTIN RELEASE; PROLACTINOMA; REVIEW; SEX DIFFERENCE; SIDE EFFECT; SIGNAL TRANSDUCTION;

EID: 0141763681     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (18)

1. Josimovich JB, Lavenhar MA, Devanesan MM, Sesta HJ, Wilchins SA, Smith AC. Heterogeneous distribution of serum prolactin values in apparently healthy young women, and the effects of oral contraceptive medication. Fertil Steril 1987;47:785-91.
2. Asa SL, Ezzat S. The pathogenesis of pituitary tumours. Nat Rev Cancer 2002;2:836-49.
3. Vallette-Kasic S, Morange-Ramos I, Selim A, Gunz G, Morange S, Enjalbert A, et al. Macroprolactinemia revisited: a study on 106 patients. J Clin Endocrinol Metab 2002;87:581-8.
4. Thodou E, Asa SL, Kontogeorgos G, Kovacs K, Horvath E, Ezzat S. Clinical case seminar: lymphocytic hypophysitis: clinicopathological findings. J Clin Endocrinol Metab 1995;80:2302-11.
5. Yermus R, Ezzat S. Does normalization of prolactin levels result in weight loss in patients with prolactin secreting pituitary adenomas? [letter] Clin Endocrinol (Oxf) 2002;56:562.
6. Biller BMK, Baum HB, Rosenthal DI, Saxe VC, Charpie PM, Klibanski A. Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhea. J Clin Endocrinol Metab 1992;75:692-7.
7. Di Somma C, Colao A, Di Sarno A, Klain M, Landi ML, Facciolli G, et al. Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males. J Clin Endocrinol Metab 1998;83:807-13.
8. Schlechte J, Dolan K, Sherman B, Chapler F, Luciano A. The natural history of untreated hyperprolactinemia: a prospective analysis. J Clin Endocrinol Metab 1989;68:412-8.
9. Di Sarno A, Landi ML, Cappabianca P, Di Salle F, Rossi FW, Pivonello R, et al. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition and therapeutic strategy. J Clin Endocrinol Metab 2001;86:5256-61.
10. De Luis DA, Becerra A, Lahera M, Botella JI, Valero, Varela C. A randomized cross-over study comparing cabergoline and quinagolide in the treatment of hyperprolactinemic patients. J Endocrinol Invest 2000;23:428-34.
11. Jeffcoate WJ, Pound N, Sturrock NDC, Lambourne J. Long-term follow-up of patients with hyperprolactinaemia. Clin Endocrinol (Oxf) 1996;45:299-303.
12. Serri O, Rasio E, Beauregard H, Hardy J, Somma M. Recurrence of hyperprolactinemia after selective transsphenoidal adenomectomy in women with prolactinoma. N Engl J Med 1983;309:280-3.
13. Serri O, Hardy J, Massoud F. Relapse of hyperprolactinemia revisited. N Engl J Med 1993;329:1357.
14. Thompson JA, Gray CE, Teasdale GM. Relapse of hyperprolactinemia after transsphenoidal surgery for microprolactinoma: lessons from long-term follow-up. Neurosurgery 2002;50:36-9.
15. Molitch ME. Management of prolactinomas during pregnancy. J Reprod Med 1999;44:1121-6.
16. Ricci E, Parazzini F, Motta T, Ferrari CI, Colao A, Clavenna A, et al. Pregnancy outcome after cabergoline treatment in early weeks of gestation. Reprod Toxicol 2002;16:791-3.
17. Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF, for the Cabergoline Comparative Study Group. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med 1994;331:904-9.
18. Passos VQ, Souza JJ, Musolino NR, Bronstein MD. Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal. J Clin Endocrinol Metab 2002;87:3578-82.